Cochrane · systematic review · CD010257

Antibiotics for exacerbations of chronic obstructive pulmonary disease

Vollenweider, DJ, Frei, A, Steurer‐Stey, CA, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library

Airways2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 20%Moderate 7 · 70%High 1 · 10%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Antibiotics compared to placebo for exacerbations of chronic obstructive pulmonary disease: outpatients

Population: exacerbations of COPD
CD010257.PUB2 (current) · 2 questions
OutcomeEffectEvidenceStatus / GRADE
Treatment failure within 4 weeks ‐ current drugs only
Antibiotics vs placebo
RR 0.72 [0.56, 0.94]7 studies · 1191 participantsLow
Downgraded: imprecision, inconsistency
All‐cause mortality
Antibiotics vs placebo
OR 1.27 [0.49, 3.3]1 study · 301 participantsLow
Downgraded: imprecision, inconsistency

Antibiotics compared to placebo for exacerbations of chronic obstructive pulmonary disease: inpatients

Population: exacerbations of COPD
CD010257.PUB2 (current) · 6 questions
OutcomeEffectEvidenceStatus / GRADE
Treatment failure within 4 weeks ‐ current drugs only ‐ inpatient
Antibiotics vs placebo
RR 0.65 [0.38, 1.12]4 studies · 576 participantsModerate
Downgraded: imprecision
Treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU
Antibiotics vs placebo
RR 0.19 [0.08, 0.45]1 study · 93 participantsModerate
Downgraded: imprecision
Duration of hospital stay (days) ‐ inpatients
Antibiotics vs placebo
no estimate extracted3 studies · 300 participantsHigh
Duration of hospital stay (days) ‐ ICU patients
Antibiotics vs placebo
no estimate extracted1 study · 94 participantsModerate
Downgraded: imprecision
All‐cause mortality ‐ inpatients
Antibiotics vs placebo
OR 2.48 [0.94, 6.55]2 studies · 214 participantsModerate
Downgraded: imprecision
All‐cause mortality ‐ ICU patients
Antibiotics vs placebo
OR 0.21 [0.06, 0.72]1 study · 93 participantsModerate
Downgraded: imprecision

Antibiotics compared to placebo overall for exacerbations of chronic obstructive pulmonary disease; adverse events

Population: exacerbations of COPD
CD010257.PUB2 (current) · 2 questions
OutcomeEffectEvidenceStatus / GRADE
Adverse events ‐ diarrhoea
Antibiotics vs placebo overall
OR 1.68 [0.92, 3.07]5 studies · 1099 participantsModerate
Downgraded: imprecision
Adverse events ‐ overall (any adverse events not specified)
Antibiotics vs placebo overall
OR 1.2 [0.89, 1.63]6 studies · 1544 participantsModerate
Downgraded: imprecision

Antibiotics for exacerbations of chronic obstructive pulmonary disease

Population: patients with exacerbations of chronic obstructive pulmonary disease
CD010257 · 7 questions
OutcomeEffectEvidenceStatus / GRADE
Treatment failure up to 4 weeks1 Subgroup: outpatient
RR 0.75 [0.6, 0.94]7 studies · 931 participantsLow
Downgraded: imprecision, inconsistency
Treatment failure up to 4 weeks1 Subgroup: inpatient
RR 0.77 [0.65, 0.91]4 studies · 612 participantsHigh
Treatment failure up to 4 weeks1 Subgoup: ICU
RR 0.19 [0.08, 0.45]1 study · 93 participantsHigh
All‐cause mortality Subgroup: inpatients
OR 1.02 [0.37, 2.79]4 studies · 531 participantsLow
Downgraded: imprecision, inconsistency
All‐cause mortality Subgroup: ICU
OR 0.21 [0.06, 0.72]1 study · 93 participantsHigh
Adverse events ‐ diarrhoea
OR 2.62 [1.11, 6.17]3 studies · 698 participantsHigh
Adverse events ‐ overall (adverse events not separated)
OR 1.53 [1.03, 2.27]5 studies · 1243 participantsModerate
Downgraded: imprecision, inconsistency